Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0TBCEQ
ADC Name
HS-20093
Synonyms
HS 20093; HS-20093; HS20093
   Click to Show/Hide
Organization
Shanghai Hansoh Biomedical Co. Ltd.
Drug Status
Phase 3
Indication
In total 6 Indication(s)
Lung cancer
Phase 3
Clinical Trial
Head and neck cancer
Phase 2
Clinical Trial
Oesophageal cancer
Phase 2
Clinical Trial
Osteosarcoma
Phase 2
Clinical Trial
Prostate cancer
Phase 2
Clinical Trial
Solid tumor
Phase 2
Clinical Trial
Drug-to-Antibody Ratio
4
Antibody Name
Risvutatug
  Antibody Info 
Antigen Name
CD276 antigen (CD276)
  Antigen Info 
Payload Name
Exatecan derivative (HS-9265)
  Payload Info 
Therapeutic Target
DNA topoisomerase 1 (TOP1)
  Target Info 
Conjugate Type
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05276609
Phase 1
ARTEMIS-001: A phase 1, open-label, multi-center study to evaluate safety, tolerability, pharmacokinetics, and efficacy of multiple doses of intravenous administration of HS-20093 in patients with locally advanced or metastatic solid tumors who have progressed following prior therapy.

   Click to Show/Hide
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05276609  Clinical Status Phase 1
Clinical Description ARTEMIS-001: A phase 1, open-label, multi-center study to evaluate safety, tolerability, pharmacokinetics, and efficacy of multiple doses of intravenous administration of HS-20093 in patients with locally advanced or metastatic solid tumors who have progressed following prior therapy.
References
Ref 1 ARTEMIS-001: A Phase 1, Open-label, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Multiple Doses of Intravenous Administration of HS-20093 in Patients With Locally Advanced or Metastatic Solid Tumors Who Have Progressed Following Prior Therapy, NCT05276609